Journal of Clinical Pediatrics ›› 2023, Vol. 41 ›› Issue (2): 92-97.doi: 10.12372/jcp.2023.22e1525

• Expert Review • Previous Articles     Next Articles

Genetic classification, diagnosis, and treatment of hyperphenylalaninemia

LIANG Lili   

  1. Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Institute for Pediatric Research, Shanghai 200092, China
  • Received:2022-11-15 Online:2023-02-15 Published:2023-02-16

Abstract:

Hyperphenylalaninemia is a group of autosomal recessive amino acid metabolic disorders, caused by defects in phenylalanine hydroxylase and its coenzyme tetrahydrobiopterin. If left untreated, severe neurological damage will occur. Treatment is based on low-phenylalanine diet therapy and neurotransmitter drug supplementation. Newborn screening for hyperphenylalaninemia began in China in 1982, more and more patients are being diagnosed during the screening. The diagnosis of hyperphenylalaninemia has shifted from the diagnosis of clinical symptoms to biochemical and genetic diagnosis in asymptomatic period. The early differential diagnosis and proper treatment for patients with hyperphenylalaninemia has become a new challenge for clinicians. Therefore, the article focuses on the genetic background, diagnosis, differential diagnosis and treatment of hyperphenylalaninemia, to raise the awareness for the disease among clinicians.

Key words: phenylalanine hydroxylase, hyperphenylalaninemia, tetrahydrobiopterin, newborn screening